Clinical Trial: Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT07455032) titled 'Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas' on Feb. 20.

Brief Summary: The goal of this clinical trial is to learn if drug CADI-05, when used together with pembrolizumab (an FDA approved immunotherapy), can help treat locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in adults. It will also learn about the safety of drug CADI-05. The main questions it aims to answer are:

* Does using CADI-05 together with pembrolizumab help the immune system fight cancer better and lead to better results for patients?

* What side effects or...